文献速递淋巴瘤

免疫豁免部位弥漫大B细胞淋巴瘤中CD37失活突变高发

High frequency of inactivating tetraspanin C D37 mutations in diffuse large B-cell lymphoma at immune-privileged sites.
PubMed 文献 · Blood · 2019-07-31

本研究对137例原发弥漫大B细胞淋巴瘤(DLBCL)样本进行CD37突变分析,其中44例为原发于睾丸或中枢神经系统的免疫豁免部位相关DLBCL(IP-DLBCL)。CD37突变仅见于IP-DLBCL病例(10/44,23%),非IP-DLBCL病例中未发现。突变包括10个错义突变、1个缺失和3个剪接位点突变,功能分析显示错义突变导致CD37蛋白在淋巴瘤B细胞质膜表达受损而功能丧失。研究提示抗CD37疗法可能对无CD37突变的DLBCL患者更获益。

要点

  • CD37突变仅见于免疫豁免部位DLBCL,发生率为23%(10/44)。
  • 突变类型包括错义、缺失和剪接位点突变,导致CD37蛋白膜表达受损。
  • 抗CD37疗法可能对无CD37突变的DLBCL患者更有效。

核心结论

  • CD37失活突变在免疫豁免部位相关DLBCL中高频发生,而在非免疫豁免部位DLBCL中缺失。
  • CD37突变导致蛋白质膜表达受损和功能丧失,提示抗CD37疗法对无突变患者更获益。

研究设计与样本

  • 对137例原发DLBCL样本进行CD37突变分析,包括44例原发于睾丸或中枢神经系统的IP-DLBCL样本。
  • 对CD37错义突变进行建模和功能分析,评估蛋白表达和功能。

主要发现

  • CD37突变仅见于IP-DLBCL病例(10/44,23%),非IP-DLBCL病例中未发现。
  • 突变包括10个错义突变、1个缺失和3个剪接位点CD37突变。
  • 错义突变导致CD37蛋白在人淋巴瘤B细胞质膜表达受损,功能丧失。

关键数值与推荐

  • IP-DLBCL中CD37突变频率为23%(10/44)。
  • CD37突变类型:10个错义突变、1个缺失、3个剪接位点突变。

临床怎么用

  • 对免疫豁免部位DLBCL患者可考虑CD37突变检测,以指导抗CD37治疗决策。
  • 抗CD37疗法可能对无CD37突变的DLBCL患者更有益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tetraspanin CD37 is predominantly expressed on the cell surface of mature B lymphocytes and is currently being studied as novel therapeutic target for B-cell lymphoma. Recently, we demonstrated that loss of CD37 induces spontaneous B-cell lymphoma in Cd37-knockout mice and correlates with inferior survival in patients with diffuse large B-cell lymphoma (DLBCL). Here, CD37 mutation analysis was performed in a cohort of 137 primary DLBCL samples, including 44 primary immune-privileged site-associated DLBCL (IP-DLBCL) samples originating in the testis or central nervous system. CD37 mutations were exclusively identified in IP-DLBCL cases (10/44, 23%) but absent in non-IP-DLBCL cases. The aberrations included 10 missense mutations, 1 deletion, and 3 splice-site CD37 mutations. Modeling and functional analysis of CD37 missense mutations revealed loss of function by impaired CD37 protein expression at the plasma membrane of human lymphoma B cells. This study provides novel insight into the molecular pathogenesis of IP-DLBCL and indicates that anti-CD37 therapies will be more beneficial for DLBCL patients without CD37 mutations.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Elfrink S, de Winde CM, van den Brand M, et al. High frequency of inactivating tetraspanin C D37 mutations in diffuse large B-cell lymphoma at immune-privileged sites. Blood. 2019. PMID: 31366619. doi:10.1182/blood.2019001185

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。